Purification of Recombinant Chemokines from E. coli

  • Amanda E. I. Proudfoot
  • Frédéric Borlat
Part of the Methods in Molecular Biology book series (MIMB, volume 138)

Abstract

The majority of chemokines are highly basic, small proteins, with a molecular mass of around 8–10 kDa. Although they do not necessarily have a high level of homology at the primary sequence level, which can be as low as 20%, although it can also be as high as 90%, the three-dimensional structure of all the chemokines solved to date has shown that they have a superimposable monomeric fold. This fold is imposed on the family by the four cysteine motif that is common to the majority of the chemokines since they all form two disulfides between Cys-1 and 3, and Cys2 and 4, whether they belong to the α or CXC or β or CC subclass. Molecular modeling of the two chemokines that deviate from the motif, the C chemokine lymphotactin which lacks a disulfide, and the CX3C chemokine neurotactin or fraktalkine which has three amino acids between the first cysteine pair, both adopt the same fold. Modeling in fact shows that either one or three residues between the first two Cys can be adopted, but not two, probably explaining why examples of CX2C chemokines do not exist.

Keywords

HPLC Urea Glutathione Cysteine Heparin 

References

  1. 1.
    Schroder J. M. (1997) Identification and structural characterization of chemokines in lesional skin material of patients with inflammatory skin disease. MethodsEnzymol. 288, 266–297.Google Scholar
  2. 2.
    Schroder J. M. (1997) Isolation and purification of neutrophil-activating peptide-4: a chemokine missing two cysteines. Methods Enzymol. 287, 216.PubMedCrossRefGoogle Scholar
  3. 3.
    Noso N., Proost P., van Damme J., and Schroder J. M. (1994) Human monocyte chemotactic proteins-2 and 3 (MCP-2 and MCP-3) attract human eosinophilsn and desensitize the chemotactic responses towards RANTES. Biochem. Biophys.Res. Commun. 200, 1470–1476.PubMedCrossRefGoogle Scholar
  4. 4.
    Proost P., Struyf S., Couvreur M., Lenaerts J. P., Conings R., Menten P., Verhaert P., Wuyts A., and van Damme J. (1998) Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J. Immunol. 160, 4034–4041.PubMedGoogle Scholar
  5. 5.
    Kuschert G. S., Hoogewerf A. J., Proudfoot A. E. I., Chung C. W., Cooke R., Hubbard R. E., Wells T. N. C., and Sanderson P. N. (1998) Identification of a glycosoaminoglaycan binding site on human interleukin-8. Biochemistry 37, 11,193–11,201.PubMedCrossRefGoogle Scholar
  6. 6.
    Proudfoot A.E., Peitsch M. C., Power C. A., Allet B., Mermod J. J., Bacon K., and Wells T. N. (1997) Structure and bioactivity of recombinant human CTAP-III and NAP-2. J. Protein Chem. 16, 37–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Alouani S., Gaertner H. F., Mermod J. J., Power C. A., Bacon K. B., Wells T. N., and A.E. Proudfoot A. E. (1995) A fluorescent interleukin-8 receptor probe produced by targetted labelling at the amino terminus. Eur. J. Biochem. 227, 328–334.PubMedCrossRefGoogle Scholar
  8. 8.
    Proudfoot A. E., Power C. A., Hoogewerf A., Montjovent M. O., Borlat F., and Wells T. N. (1995) Characterisation of the RANTES/MIP-1 alpha receptor (CC CKR-1) stably transfected in HEK 293 cells and the recombinant ligands. FEBS Lett. 376, 19–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Solari R., Offord R. E., Remy S., Aubry J. P., Wells T. N., Whitehorn E., Oung T., and Proudfoot A. E. (1997) Receptor-mediated endocytosis of CC-chemokines. J. Biol. Chem. 272, 9617–9620.PubMedCrossRefGoogle Scholar
  10. 10.
    Proudfoot A. E., Power C. A., Hoogewerf A. J., Montjovent M. O., Borlat F., Offord R. E., and Wells T. N. (1996) Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol.Chem. 271, 2599–2603.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Amanda E. I. Proudfoot
    • 1
  • Frédéric Borlat
    • 1
  1. 1.Serono Pharmaceutical Research Institute S AGenevaSwitzerland

Personalised recommendations